A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro

[1]  T. Reinheckel,et al.  In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow , 2017, The Journal of Nuclear Medicine.

[2]  A. Castor,et al.  Parents’ and Adolescents’ Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials , 2016, Pediatric blood & cancer.

[3]  C. Bloomfield,et al.  Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665 , 2016, Leukemia & lymphoma.

[4]  N. Hijiya,et al.  Asparaginase-associated toxicity in children with acute lymphoblastic leukemia , 2015, Leukemia & lymphoma.

[5]  C. Rizzari.  Still trying to pick the best asparaginase preparation. , 2015, The Lancet. Oncology.

[6]  A. Lamb,et al.  Towards "next-generation" prostate cancer screening. , 2015, The Lancet. Oncology.

[7]  H. Dombret,et al.  A Phase 2 study of L‐asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL‐SA2‐2008 study , 2015, American journal of hematology.

[8]  J. Weinstein,et al.  Catalytic Role of the Substrate Defines Specificity of Therapeutic l-Asparaginase. , 2015, Journal of molecular biology.

[9]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[10]  S. Mittelman,et al.  Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. , 2015, Leukemia research.

[11]  C. Harrison,et al.  Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. , 2015, Blood.

[12]  G. Colombo,et al.  Mechanisms of Differential Allosteric Modulation in Homologous Proteins: Insights from the Analysis of Internal Dynamics and Energetics of PDZ Domains. , 2014, Journal of chemical theory and computation.

[13]  A. Sonawane,et al.  Improvement of stability and enzymatic activity by site-directed mutagenesis of E. coli asparaginase II. , 2014, Biochimica et biophysica acta.

[14]  Ashok Pandey,et al.  Effect of surface charge alteration on stability of L-asparaginase II from Escherichia sp. , 2014, Enzyme and microbial technology.

[15]  R. Read,et al.  Automating crystallographic structure solution and refinement of protein–ligand complexes , 2013, Acta crystallographica. Section D, Biological crystallography.

[16]  Paul D. Adams,et al.  Ligand placement based on prior structures: the guided ligand-replacement method , 2013, Acta crystallographica. Section D, Biological crystallography.

[17]  S. Mittelman,et al.  Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. , 2013, Cancer research.

[18]  Ivan Merelli,et al.  Molecular Mechanism of Allosteric Communication in Hsp70 Revealed by Molecular Dynamics Simulations , 2012, PLoS Comput. Biol..

[19]  Morten Nielsen,et al.  Reliable B Cell Epitope Predictions: Impacts of Method Development and Improved Benchmarking , 2012, PLoS Comput. Biol..

[20]  O. Podobed,et al.  Antitumor activity of L-asparaginase from Erwinia carotovora against different human and animal leukemic and solid tumor cell lines , 2012, Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry.

[21]  A. Masood,et al.  Role of proteases in cancer: A review , 2012 .

[22]  Gordon A Leonard,et al.  ID29: a high-intensity highly automated ESRF beamline for macromolecular crystallography experiments exploiting anomalous scattering. , 2012, Journal of synchrotron radiation.

[23]  Giorgio Colombo,et al.  Corresponding Functional Dynamics across the Hsp90 Chaperone Family: Insights from a Multiscale Analysis of MD Simulations , 2012, PLoS Comput. Biol..

[24]  L. Chiarelli,et al.  Expanding targets for a metabolic therapy of cancer: L-asparaginase. , 2012, Recent patents on anti-cancer drug discovery.

[25]  O. Schilling,et al.  Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. , 2011, Journal of proteome research.

[26]  Holger Gohlke,et al.  A Normal Mode-Based Geometric Simulation Approach for Exploring Biologically Relevant Conformational Transitions in Proteins , 2011, J. Chem. Inf. Model..

[27]  H. Dombret,et al.  l‐asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005‐01 randomized trial , 2011, British journal of haematology.

[28]  Owen Johnson,et al.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM , 2011, Acta crystallographica. Section D, Biological crystallography.

[29]  Marc N. Offman,et al.  Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. , 2011, Blood.

[30]  J. V. van Dongen,et al.  Genetic aberrations in paediatric acute leukaemias and implications for management of patients. , 2010, The Lancet. Oncology.

[31]  Gennady Verkhivker,et al.  Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90. , 2010, Journal of chemical theory and computation.

[32]  C. M. Cadwell,et al.  Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice. , 2009, The Journal of clinical investigation.

[33]  Marc N. Offman,et al.  A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. , 2009, The Journal of clinical investigation.

[34]  Giorgio Colombo,et al.  Modeling Signal Propagation Mechanisms and Ligand-Based Conformational Dynamics of the Hsp90 Molecular Chaperone Full-Length Dimer , 2009, PLoS Comput. Biol..

[35]  Wei Li,et al.  ElliPro: a new structure-based tool for the prediction of antibody epitopes , 2008, BMC Bioinformatics.

[36]  Carrie Cupp-Enyard.  Sigma's Non-specific Protease Activity Assay - Casein as a Substrate , 2008, Journal of visualized experiments : JoVE.

[37]  X. Thomas,et al.  L-Asparaginase Loaded into Erythrocytes (GRASPA): Principle and Interests in Acute Lymphoblastic Leukemia. , 2007 .

[38]  C. Fu,et al.  PEG-asparaginase , 2007, Expert opinion on pharmacotherapy.

[39]  V. Avramis,et al.  Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia , 2006, International journal of nanomedicine.

[40]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[41]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[42]  C. Harrison,et al.  Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia , 2005, Leukemia.

[43]  E. Panosyan,et al.  Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations , 2005, Clinical pharmacokinetics.

[44]  D. Kyriakidis,et al.  Antiproliferative activity of L-asparaginase of Tetrahymena pyriformis on human breast cancer cell lines , 1990, Molecular and Cellular Biochemistry.

[45]  J. Kurtzberg,et al.  A Phase I–II trial of polyethylene glycol‐conjugated L‐asparaginase in patients with multiple myeloma , 2003, Cancer.

[46]  J. Whitelegge,et al.  Full Subunit Coverage Liquid Chromatography Electrospray Ionization Mass Spectrometry (LCMS+) of an Oligomeric Membrane Protein , 2002, Molecular & Cellular Proteomics.

[47]  B. Polakiewicz,et al.  Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase. , 2002, International journal of pharmaceutics.

[48]  D. Schomburg,et al.  BRENDA: a resource for enzyme data and metabolic information. , 2002, Trends in biochemical sciences.

[49]  Charles W. Taylor,et al.  A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors , 2001, Cancer Chemotherapy and Pharmacology.

[50]  C. Derst,et al.  Engineering the substrate specificity of Escherichia coli asparaginase II. Selective reduction of glutaminase activity by amino acid replacements at position 248 , 2000, Protein science : a publication of the Protein Society.

[51]  G. Sorrentino,et al.  Kinetics and mechanism of the cleavage of the peptide bond next to asparagine , 1996, Peptides.

[52]  S. Gottesman,et al.  Proteases and their targets in Escherichia coli. , 1996, Annual review of genetics.

[53]  M. Jaskólski,et al.  Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. Lestingi,et al.  Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1993, Hematology/oncology clinics of North America.

[55]  J. Kaper,et al.  Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector , 1991, Infection and immunity.

[56]  I. Beacham,et al.  Analysis of the Escherichia coli gene encoding L-asparaginase II, ansB, and its regulation by cyclic AMP receptor and FNR proteins , 1990, Journal of bacteriology.

[57]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[58]  E. Henderson,et al.  Distinctive sensitivity of some T-leukemia cell lines to L-asparaginase. , 1984, Gan.

[59]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[60]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[61]  E. Freireich,et al.  L‐asparaginase for the treatment of cancer , 1973, CA: a cancer journal for clinicians.

[62]  栄三 垣下,et al.  L-asparaginase 療法に関する考察 , 1972 .

[63]  B. Kim,et al.  L-asparaginase in the treatment of neoplastic diseases in children. , 1971, Cancer research.

[64]  R. Handschumacher,et al.  Immunological responses to L-asparaginase. , 1971, The Journal of clinical investigation.

[65]  S. Shapiro,et al.  An Analysis of Variance Test for Normality (Complete Samples) , 1965 .

[66]  P. Edman,et al.  A method for the determination of amino acid sequence in peptides. , 1949, Archives of biochemistry.

[67]  O. Folin,et al.  ON TYROSINE AND TRYPTOPHANE DETERMINATIONS IN PROTEINS , 1927 .